Precision Medicine: Genetic Repair of Retinitis Pigmentosa in Patient-Derived Stem Cells

Scientific Reports
Alexander G BassukVinit B Mahajan

Abstract

Induced pluripotent stem cells (iPSCs) generated from patient fibroblasts could potentially be used as a source of autologous cells for transplantation in retinal disease. Patient-derived iPSCs, however, would still harbor disease-causing mutations. To generate healthy patient-derived cells, mutations might be repaired with new gene-editing technology based on the bacterial system of clustered regularly interspersed short palindromic repeats (CRISPR)/Cas9, thereby yielding grafts that require no patient immunosuppression. We tested whether CRISPR/Cas9 could be used in patient-specific iPSCs to precisely repair an RPGR point mutation that causes X-linked retinitis pigmentosa (XLRP). Fibroblasts cultured from a skin-punch biopsy of an XLRP patient were transduced to produce iPSCs carrying the patient's c.3070G > T mutation. The iPSCs were transduced with CRISPR guide RNAs, Cas9 endonuclease, and a donor homology template. Despite the gene's repetitive and GC-rich sequences, 13% of RPGR gene copies showed mutation correction and conversion to the wild-type allele. This is the first report using CRISPR to correct a pathogenic mutation in iPSCs derived from a patient with photoreceptor degeneration. This important proof-of-concept f...Continue Reading

References

Aug 10, 2000·Nature Genetics·R VervoortA F Wright
Nov 10, 2006·Nature·R E MacLarenR R Ali
Apr 29, 2008·The New England Journal of Medicine·James W B BainbridgeRobin R Ali
Oct 20, 2009·Nature Methods·Tongxiang LinSheng Ding
Jun 30, 2012·Science·Martin JinekEmmanuelle Charpentier
Aug 3, 2013·Nucleic Acids Research·Luhan YangGeorge Church
Feb 4, 2014·The British Journal of Ophthalmology·Alexander G BassukVinit B Mahajan
May 6, 2015·The New England Journal of Medicine·James W B BainbridgeRobin R Ali

❮ Previous
Next ❯

Citations

Oct 5, 2016·Human Genetics·M PhanC E L Carels
Dec 3, 2016·Regenerative Medicine·Erin A Kimbrel, Robert Lanza
Nov 20, 2016·American Journal of Medical Genetics. Part C, Seminars in Medical Genetics·Jesse D SengilloStephen H Tsang
Mar 8, 2016·Journal of Cellular Physiology·Ganesan Govindan, Sivaprakash Ramalingam
Jan 31, 2017·Genes·Jesse D SengilloStephen H Tsang
Jan 24, 2017·Progress in Retinal and Eye Research·Melissa K JonesShaomei Wang
Jun 18, 2017·Experimental Eye Research·Wenyi WuHetian Lei
Feb 1, 2017·Current Opinion in Ophthalmology·Thiago CabralStephen H Tsang
Sep 17, 2016·Journal of Pediatric Ophthalmology and Strabismus·Julie Shabto
Jul 12, 2017·Expert Opinion on Biological Therapy·Andrew J SmithBreandán N Kennedy
Mar 9, 2018·Molecular Biotechnology·Minjung Song, Suresh Ramakrishna
Aug 19, 2017·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Shaoqing HeThomas Yorio
Jan 19, 2018·Stem Cells·Ana Artero CastroSlaven Erceg
Aug 23, 2017·Journal of Neural Engineering·Priya R Gupta, Rachel M Huckfeldt
Jul 18, 2018·Annals of Human Genetics·Sleiman Razzouk
Nov 30, 2018·Genes·David J JiangStephen H Tsang
May 10, 2019·Investigative Ophthalmology & Visual Science·Jose Ronaldo Lima de CarvalhoJanet R Sparrow
Mar 10, 2020·PLoS Genetics·Maria KaukonenUNKNOWN DoGA Consortium
Apr 2, 2020·International Journal of Molecular Sciences·Caroline F PeddleRobert E MacLaren
Jun 3, 2016·Oncotarget·Faheem Ahmed KhanZhang ShuJun
Dec 21, 2019·Journal of Medical Genetics·Daniela BenatiAlessandra Recchia
Aug 16, 2016·Current Opinion in Organ Transplantation·Peter J Cowan
Jun 15, 2018·International Journal of Oncology·Stella BaliouVassilis Zoumpourlis
Feb 17, 2017·Nature Reviews. Rheumatology·Gary J Gibson, Maozhou Yang
Apr 5, 2016·Oral Diseases·A Peterson
Apr 21, 2017·Frontiers in Neuroscience·Peter M QuinnJan Wijnholds
May 24, 2017·Science China. Life Sciences·Ke MenYuquan Wei
May 11, 2018·Retina·Galaxy Y ChoVinit B Mahajan
Aug 21, 2018·Stem Cells International·Nina XieBeisha Tang
Jan 4, 2019·Human Genetics·Cheryl Y Gregory-EvansKevin Gregory-Evans
Aug 5, 2016·Asia-Pacific Journal of Ophthalmology·Micah A ChrenekJeffrey H Boatright
Apr 28, 2017·Japanese Journal of Ophthalmology·Kengo IkesugiMineo Kondo
Feb 7, 2017·Expert Review of Ophthalmology·Benjamin Bakondi
Jun 2, 2018·The Journal of Clinical Investigation·James E DiCarloStephen H Tsang
Jun 9, 2020·Asia-Pacific Journal of Ophthalmology·Mays Talib, Camiel J F Boon
Apr 14, 2017·Cellular and Molecular Life Sciences : CMLS·Arun Pandian ChandrasekaranSuresh Ramakrishna
Oct 3, 2017·Current Ophthalmology Reports·Galaxy Y ChoVinit B Mahajan
Jan 13, 2019·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Vitor K L TakahashiStephen H Tsang
Jun 8, 2018·Frontiers in Cell and Developmental Biology·Christine L XuStephen H Tsang
Jun 2, 2018·Neural Plasticity·Carla Sanjurjo-Soriano, Vasiliki Kalatzis

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
GTPase
PCR
amplicon sequencing
exome sequencing
transfection

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR Genome Editing & Therapy

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of this system for gene editing and therapy in human diseases.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

Biophysics of CRISPR

This feed focuses on broad characteristics of the CRISPR system and the proteins associated with it.